Pharmaceuticals

FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

DARMSTADT, Germany and NEW YORK, July 1, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with...

2020-07-01 07:30 7760

Carmine Therapeutics and Takeda Collaborate to Discover and Develop Rare Disease Gene Therapies Using Novel Red Blood Cell Extracellular Vesicles Platform

CAMBRIDGE, Mass., July 1, 2020 /PRNewswire/ -- Carmine Therapeutics announced today that it has signed a research collaboration agreement with Takeda Pharmaceutical Company Limited ("Takeda") to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targ...

2020-07-01 07:00 2677

AGC Biologics Expands Development Capacities for pDNA Services at Heidelberg Site

Expansion will help meet the growing demand for plasmid DNA offerings SEATTLE, June 30, 2020 /PRNewswire/ -- Committed to continuous innovation and expansion of its service offerings, AGC Biologics has announced the expansion of its pDNA Center of Excellence in Heidelberg, Germany. The global bi...

2020-06-30 21:00 2346

Release of Initial Attana Virus Analytics-AVA Testing Protocols

STOCKHOLM, June 30, 2020 /PRNewswire/ -- Attana has today released the initial technical protocols for AVA Antibody Testing and will make these available to all existing Attana customers. In close collaboration with Linnaeus University Attana application specialists have been performing studies ...

2020-06-30 15:42 1262

'Curing Cancer without Surgery'

* "Successful disappearance of tumors in subjects upon administering the pain-free anticancer drug, Polytaxel, without side effects such as weight loss." * Suppressed 99.8% of tumors despite a non-toxic dose…more effective than existing FDA-approved pancreatic cancer drugs. * Hopes for a Kore...

2020-06-30 15:10 1512

Thrombosis Research Institute (TRI) Announce ETHIC Trial to Evaluate the Potential Benefits of Early Administration of LMWH in Patients with COVID-19

- Clinical trial will recruit approximately 1400 patients in 10 countries starting in July  - Participants will be randomised to receive the low molecular weight Heparin enoxaparin or current standard of care for up to 3 weeks from the time of diagnosis  - The study is supported through an inve...

2020-06-30 14:00 1811

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

AOBiome's 576 patient Phase 2b trial commences patient enrollment CAMBRIDGE, Massachusetts, June 30, 2020 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on inflammation,  announced initiation of a Phase2b clinical trial in pruritus (i...

2020-06-30 13:00 1151

Alterity Therapeutics meeting with US FDA provides development pathway for ATH434

MELBOURNE, Australia and SAN FRANCISCO, June 29, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434 ...

2020-06-30 11:14 5985

MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon

NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease. This includes indications for both de-novo lesions as well as in-stent ...

2020-06-30 08:00 2231

China Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin Transaction

BEIJING, June 29, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today declared that the Company disagrees with the notice delivered by Xinjiang Deyuan Bioeng...

2020-06-29 13:00 11910

Qiming's Portfolio Company Gan & Lee Pharmaceuticals Lands A-Shares Main Board

SHANGHAI, June 29, 2020 /PRNewswire/ -- Chinese insulin manufacturer Gan & Lee Pharmaceuticals (SHSE: 603087), Qiming's portfolio company today lands on the A-shares main board market. The issue price of Gan & Lee isRMB 63.32 per share. The stock opens atRMB 91.18 per share, up 44%, with a market...

2020-06-29 11:31 3325

Loss of Function Variant in FLT3 Strongly Increases the Risk of Autoimmune Thyroid Disease and Other Autoimmune Diseases

The combination of genomics, transcriptomics and proteomics sheds light on autoimmune thyroid disease, other autoimmune diseases and AML REYKJAVIK, Iceland, June 24, 2020 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from the Icelandic healthcare s...

2020-06-24 23:00 3162

Global Fund COVID-19 Report: Deaths from HIV, TB and Malaria Could Almost Double in 12 Months Unless Urgent Action is Taken

GENEVA, June 24, 2020 /PRNewswire/ -- A new report released by the Global Fund today estimates that countries affected by HIV, tuberculosis and malaria urgently needUS$28.5 billion to protect the extraordinary progress achieved in the fight against the three diseases in the past two decades. The...

2020-06-24 16:31 1484

Akeso Appoints Prof. Bradley Monk as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee

LOS ANGELES, June 24, 2020 /PRNewswire/ -- Akeso, Inc. ("Akeso", 9926.HK) announced the appointment of ProfessorBradley J. Monk, MD, FACOG[1], FACS[2] as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee for its global Phase 2, multicentre registration study to evaluate the ef...

2020-06-24 12:55 7232

Mayne Pharma Announces FDA Filing Acceptance of New Drug Application for E4/DRSP in the US

ADELAIDE, Australia, June 24, 2020 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in ...

2020-06-24 12:10 5798

InxMed Released Research Data of "FAK inhibitor IN10018 overcomes drug resistance of KRAS G12C inhibition" at 2020 AACR Annual Meeting

SHANGHAI, June 24, 2020 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced that the company has released the research data of "FAK inhibitor IN10018...

2020-06-24 08:41 2121

IgNova Files Patent Application on Antibody Against COVID-19

VISBEK, Germany, June 24, 2020 /PRNewswire/ -- IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (I...

2020-06-24 02:13 1653

ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA

SAN DIEGO, June 22, 2020 /PRNewswire/ -- ABM Therapeutics, a clinical-stage biopharmaceutical company developing a new generation of BRAF inhibitor, today announced that the first cancer patient has been successfully enrolled and dosed with ABM-1310 in the Phase 1 clinical trial in theUSA. ABM-13...

2020-06-22 23:00 4275

Cutting-edge Multidisciplinary Approaches to Minimally Invasive Cancer Treatment Utilizing JCI MN COLLOIDAL IODINE (R) and Possible Effect on SARS-CoV-2

TOKYO, June 22, 2020 /PRNewswire/ -- On June 10, 2020, JCI MN IODINE Co., Ltd. released the following new information regarding the therapeutic usefulness of JCI MN IODINE agents.Ryusuke Fujiki, Clinical Head and President of Fujiki Hospital, announced "minimally invasive, multidisciplinary treat...

2020-06-22 13:00 1060

Qiming's Portfolio Company SinocellTech Lands on STAR Market

SHANGHAI, June 22, 2020 /PRNewswire/ -- Chinese biologic drug developer SinocellTech, Qiming's portfolio company, today lands on the Science and Technology Innovation Board (the STAR Market). The issue price of SinocellTech (SHSE: 688520) isCNY 25.64 per share. The stock opens at CNY 85 per share...

2020-06-22 12:20 2454
1 ... 289290291292293294295 ... 313

Week's Top Stories